![]() |
|
|
Vol. 303, Issue 1, 308-313, October 2002
-Tocopheryl Poly(Ethylene
Glycol 1000) Succinate
AvMax Inc., South San Francisco, California (V.J.W., J.A.S., S.W.,
P.T.-T., A.O.C., A.C.) and Elan Pharmaceutical Technologies, Dublin,
Ireland (X.-Q.Y., D.O.M., Z.R.)
The contributions of cytochrome P450 3A (CYP3A) and
P-glycoprotein to sirolimus oral bioavailability in rats were evaluated by coadministration of sirolimus (Rapamune) with the CYP3A inhibitor ketoconazole or the P-glycoprotein inhibitor
D-
-tocopheryl poly(ethylene glycol 1000) succinate
(TPGS). Groups of six male Sprague-Dawley rats (250-300 g) were
administered Rapamune (1 mg/kg) by oral gavage, alone and with
ketoconazole (30 mg/kg) or TPGS (50 mg/kg). Sirolimus levels were
measured in whole blood over a 6-h time course. Sirolimus
Cmax (6.6 ± 1.6 versus 26 ± 7 ng/ml) and area under the concentration versus time curve from 0 to
6 h (AUC0-6) (22 ± 7 versus 105 ± 27 ng · h/ml) were increased 3- to 5-fold by ketoconazole. Median
Tmax (1.5-2 h) was unchanged. TPGS had no
effect on sirolimus absorption. The interaction of sirolimus with
P-glycoprotein was also evaluated in vitro using HCT-8 and Caco-2 cell
monolayers. Consistent with published reports, sirolimus was a good inhibitor of P-glycoprotein, inhibiting polarized
basolateral-to-apical flux of rhodamine 123 with an IC50 of
0.625 to 1.25 µM (cyclosporine caused >80% inhibition at 5 µM).
Sirolimus did not demonstrate significant polarized flux in either
direction using the same monolayers (basolateral-to-apical flux was <2
times the apical-to-basolateral). Moreover, sirolimus flux was not
impacted by cyclosporine, suggesting that it does not undergo
P-glycoprotein-mediated transport in this system. The lack of
significant sirolimus transport by P-glycoprotein may, in part, explain
the lack of a TPGS effect on sirolimus absorption in rats.
This article has been cited by other articles:
![]() |
N. Picard, N. Djebli, F.-L. Sauvage, and P. Marquet Metabolism of Sirolimus in the Presence or Absence of Cyclosporine by Genotyped Human Liver Microsomes and Recombinant Cytochromes P450 3A4 and 3A5 Drug Metab. Dispos., March 1, 2007; 35(3): 350 - 355. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Cummins, W. Jacobsen, U. Christians, and L. Z. Benet CYP3A4-Transfected Caco-2 Cells as a Tool for Understanding Biochemical Absorption Barriers: Studies with Sirolimus and Midazolam J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 143 - 155. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Tamura, Y. Tokunaga, R. Ibuki, G. L. Amidon, H. Sezaki, and S. Yamashita The Site-Specific Transport and Metabolism of Tacrolimus in Rat Small Intestine J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 310 - 316. [Abstract] [Full Text] [PDF] |
||||